Chlorthalidone in Chronic Kidney Disease

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: advancedtherapymoderate totransplantrandomization
  Phrases that lowered it: use ofmmhgkgmassdrugs
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.5% (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 7.2% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 41 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 229 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 68.1% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial NCT03923933 · started 2019 · scored riskier than 36% of active trials completed
• Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus NCT02644395 · started 2013 · scored riskier than 36% of active trials completed
• VA NEPHRON-D: Diabetes iN Nephropathy Study NCT00555217 · started 2008 · scored riskier than 29% of active trials terminated
• A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes NCT05254002 · started 2022 · scored riskier than 20% of active trials completed
• A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease NCT05047263 · started 2021 · scored riskier than 35% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.